RASRx Overview

  • Founded
  • 2014
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Investors
  • 2

RASRx General Information


Developer of an oral therapy designed to provide improved muscle strength and regeneration, with decreased muscle inflammation and fibrosis. The company's therapy has shown positive effects on muscle function in an MDX mouse model and potentially reverse disease progression to bring relief to patients, and possibly other muscular dystrophies, enabling physicians with complex muscle pathology for the treatment of Duchenne muscular dystrophy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 231 Bonetti Drive
  • Suite 240
  • San Luis Obispo, CA 93401
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

RASRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 06-Jan-2016 Completed Generating Revenue
1. Grant 11-Nov-2015 000 Completed Generating Revenue
To view RASRx’s complete valuation and funding history, request access »

RASRx Executive Team (2)

Name Title Board Seat Contact Info
Kathleen Rodgers Co-Founder
Kevin Gaffney Co-Founder
To view RASRx’s complete executive team members history, request access »

RASRx Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
To view RASRx’s complete investors history, request access »